Segregation of functional networks is associated with cognitive resilience in Alzheimer's disease.


Journal

Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537

Informations de publication

Date de publication:
17 08 2021
Historique:
received: 02 09 2020
revised: 26 11 2020
accepted: 29 12 2020
pubmed: 17 3 2021
medline: 25 9 2021
entrez: 16 3 2021
Statut: ppublish

Résumé

Cognitive resilience is an important modulating factor of cognitive decline in Alzheimer's disease, but the functional brain mechanisms that support cognitive resilience remain elusive. Given previous findings in normal ageing, we tested the hypothesis that higher segregation of the brain's connectome into distinct functional networks represents a functional mechanism underlying cognitive resilience in Alzheimer's disease. Using resting-state functional MRI, we assessed both resting-state functional MRI global system segregation, i.e. the balance of between-network to within-network connectivity, and the alternate index of modularity Q as predictors of cognitive resilience. We performed all analyses in two independent samples for validation: (i) 108 individuals with autosomal dominantly inherited Alzheimer's disease and 71 non-carrier controls; and (ii) 156 amyloid-PET-positive subjects across the spectrum of sporadic Alzheimer's disease and 184 amyloid-negative controls. In the autosomal dominant Alzheimer's disease sample, disease severity was assessed by estimated years from symptom onset. In the sporadic Alzheimer's sample, disease stage was assessed by temporal lobe tau-PET (i.e. composite across Braak stage I and III regions). In both samples, we tested whether the effect of disease severity on cognition was attenuated at higher levels of functional network segregation. For autosomal dominant Alzheimer's disease, we found higher functional MRI-assessed system segregation to be associated with an attenuated effect of estimated years from symptom onset on global cognition (P = 0.007). Similarly, for patients with sporadic Alzheimer's disease, higher functional MRI-assessed system segregation was associated with less decrement in global cognition (P = 0.001) and episodic memory (P = 0.004) per unit increase of temporal lobe tau-PET. Confirmatory analyses using the alternate index of modularity Q revealed consistent results. In conclusion, higher segregation of functional connections into distinct large-scale networks supports cognitive resilience in Alzheimer's disease.

Identifiants

pubmed: 33725114
pii: 6174116
doi: 10.1093/brain/awab112
pmc: PMC8370409
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

2176-2185

Subventions

Organisme : Medical Research Council
ID : MR/L023784/1
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : U01 AG024904
Pays : United States
Organisme : NIA NIH HHS
ID : U19 AG024904
Pays : United States
Organisme : MRC
ID : MR/L023784/1
Organisme : Medical Research Council
ID : MR/L023784/2
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : U19 AG032438
Pays : United States

Informations de copyright

© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Michael Ewers (M)

Institute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilian-University LMU, Munich, Germany.
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.

Ying Luan (Y)

Institute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilian-University LMU, Munich, Germany.

Lukas Frontzkowski (L)

Institute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilian-University LMU, Munich, Germany.

Julia Neitzel (J)

Institute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilian-University LMU, Munich, Germany.

Anna Rubinski (A)

Institute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilian-University LMU, Munich, Germany.

Martin Dichgans (M)

Institute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilian-University LMU, Munich, Germany.
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Munich Cluster for Systems Neurology, SyNergy, Ludwig-Maximilian-University LMU, Munich, Germany.

Jason Hassenstab (J)

Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA.
Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA.
Department of Psychological and Brain Sciences, Washington University, St. Louis, MO, USA.

Brian A Gordon (BA)

Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA.
Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA.
Department of Psychological and Brain Sciences, Washington University, St. Louis, MO, USA.

Jasmeer P Chhatwal (JP)

Massachusetts General Hospital, Department of Neurology, Harvard Medical School, MA, USA.

Johannes Levin (J)

German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany.

Peter Schofield (P)

Neuroscience Research Australia, Sydney, NSW, Australia.
School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia.

Tammie L S Benzinger (TLS)

Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA.
Department of Radiology, Washington University in St Louis, St Louis, MO, USA.

John C Morris (JC)

Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA.
Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA.
Department of Psychiatry, Washington University in St. Louis, St. Louis, MO, USA.

Alison Goate (A)

Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ronald M. Loeb Center for Alzheimer's Disease, Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Celeste M Karch (CM)

Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA.
Department of Psychiatry, Washington University in St. Louis, St. Louis, MO, USA.
Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO, USA.

Anne M Fagan (AM)

Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA.
Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA.
Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO, USA.

Eric McDade (E)

Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA.
Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA.

Ricardo Allegri (R)

Department of Neurology, FLENI Fondation, Buenos Aires, Argentina.

Sarah Berman (S)

Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.

Helena Chui (H)

Alzheimer's Disease Research Center, Keck School of Medicine at the University of Southern California, Los Angeles, CA, USA.
Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Carlos Cruchaga (C)

Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA.
Department of Psychiatry, Washington University in St. Louis, St. Louis, MO, USA.
Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO, USA.
NeuroGenomics and Informatics, Washington University School of Medicine, St. Louis, MO, USA.

Marty Farlow (M)

Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA.

Neill Graff-Radford (N)

Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.

Mathias Jucker (M)

German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, Tübingen, Germany.
Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany.

Jae-Hong Lee (JH)

Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Ralph N Martins (RN)

Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
Australian Alzheimer's Research Foundation, Ralph and Patricia Sarich Neuroscience Research Institute, Nedlands, WA, Australia.
Department of Biomedical Sciences, Macquarie University, Sydney, NSW, Australia.
KaRa Institute of Neurological Diseases, Sydney, NSW, Australia.

Hiroshi Mori (H)

Department of Clinical Neuroscience, Osaka City University Medical School, Osaka, Japan.

Richard Perrin (R)

Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA.
Hope Center for Neurological Disorders, Washington University in St. Louis, St. Louis, MO, USA.
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.

Chengjie Xiong (C)

Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA.
Department of Biostatistics, Washington University, St Louis, MO, USA.

Martin Rossor (M)

Dementia Research Centre, University College London, Queen Square, London, UK.

Nick C Fox (NC)

Dementia Research Centre, University College London, Queen Square, London, UK.

Antoinette O'Connor (A)

Dementia Research Centre, University College London, Queen Square, London, UK.
UK Dementia Research Institute at UCL, UCL, London, UK.

Stephen Salloway (S)

Department of Neurology, Warren Alpert Medical School of Brown University, Providence, RI, USA.

Adrian Danek (A)

Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany.

Katharina Buerger (K)

Institute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilian-University LMU, Munich, Germany.
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.

Randall J Bateman (RJ)

Knight Alzheimer's Disease Research Center, Washington University in St. Louis, St. Louis, MO, USA.
Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA.

Christian Habeck (C)

Cognitive Neuroscience Division, Department of Neurology, Columbia University, New York, NY, USA.

Yaakov Stern (Y)

Cognitive Neuroscience Division, Department of Neurology, Columbia University, New York, NY, USA.

Nicolai Franzmeier (N)

Institute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilian-University LMU, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH